Open access
Predicting continuous amyloid PET levels with CSF and plasma brain‐derived p‐tau217
Lydia Trudel
J. Therriault
Arthur C. Macedo
É. Aumont
S. A. Hosseini
A. Benedet
L. Hazrati
S. Gauthier
H. Zetterberg
P. Vitali
N. Ashton
P. Rosa-Neto
Medicine
Abstract
Staging amyloid beta (Aβ) burden along a continuous spectrum provides clinically relevant information. Conventional phosphorylated tau (p‐tau)217 reliably identifies amyloid positron emission tomography (PET) positivity, but its ability to capture the full Aβ continuum is limited. Recently developed brain‐derived (BD) p‐tau217 assays enrich for central nervous system tau species and may improve specificity.